Multidisciplinary Team Approach in Cancer Care: A Review of The …
2021年11月18日 · Disclosure: Scott has declared no conflicts of interest. Support: The publication of this article was funded by a medical educational grant from AstraZeneca with the purpose of enhancing the fundamental understanding of oncology specialists of the value of a multidisciplinary team (MDT) approach in the management of patients with cancer.
EMJ | Elevating the quality of healthcare globally
This week, Jonathan is joined by David Gómez-Almaguer, Head of the Haematology Service at University Hospital Monterrey, Mexico. They discuss advancements in stem cell transplantation, the state of haematology in Latin America, and the future of innovative therapies in the field.
- [PDF]
Abstract Highlights
The following highlights showcase late-breaking research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024.
EULAR 2024 Abstract Highlights - European Medical Journal
2024年7月25日 · Axial Involvement in Psoriatic Arthritis and Spondyloarthritis. RESEARCH on axial involvement in psoriatic arthritis (PsA) and spondyloarthritis (SpA) presented at the annual EULAR 2024 Congress, determined the proportion of axial psoriatic arthritis (axPsA) among patients with PsA, as well as how it is diagnosed in clinical practice and the clinical and demographic characteristics associated ...
- [PDF]
Abstract Highlights
The following abstract highlights spotlight selected abstracts presented at the European Respiratory Society (ERS) Congress 2024. They cover key topics, including lung cancer screening
What does Trump’s win mean for pharma? - emjreviews.com
2024年11月6日 · Words by Jade Williams. With Donald Trump securing a second presidential term and his party taking control of the Senate, the US pharmaceutical industry enters a period that could bring both continuity and change over the next four years.
INTRODUCTION Endometrial cancer is one of the most 20,21 common gynaecological cancers in high-income countries,1 often presents at an early stage,2 and is frequently associated with comorbidities.3 In contrast to many other cancer types, the
AAD 2024 Congress Review Creative Commons Attribution-Non Commercial 4.0 April 2024 Dermatology 11
Why EGFR Exon 21 L858R Mutations Should Be Treated Differently
BACKGROUND. EGFR gene mutations have been reported in 15–60% of non-small cell lung cancers (NSCLCs) with an important difference in prevalence between Eastern and Western populations. 1,2 The most common EGFR-activating mutations in NSCLC include in-frame deletions in exon 19 and a substitution in exon 21 (L858R) which account for 47% and 41%, respectively, of observed EGFR mutations in ...
CC Y-NC 4. Licence É Copyright 224 EM É October 224 É Oncology 25 stressed. However, work is still needed to identify which patients with dMMR EC might not benefit ...